Headache Disorders (Cluster & Migraine)
Psychedelics are being researched as potential treatments for headache disorders, including migraines and cluster headaches, which affect a significant portion of the global population. Early findings indicate that psychedelics may modulate pain perception and offer novel therapeutic pathways for those suffering from these debilitating conditions.
Key Insights
- 1
Psychedelics, including LSD and psilocybin, have shown promise in aborting headache attacks and extending remission periods.
- 2
Activation of 5-HT2A receptors by psychedelics may help mitigate pain signals and reduce inflammation associated with headache disorders.
- 3
Initial studies indicate that a single dose of compounds like LSD may stop cluster headache cycles effectively, while psilocybin can significantly reduce migraine days.
- 4
Emerging therapies focus on non-hallucinogenic psychedelic derivatives, aiming for safer treatment options without psychoactive effects.
- 5
Research shows about 60% of LSD users report substantial reductions in the frequency of cluster headaches.
What is Headache Disorders (Cluster & Migraine)?
Headache disorders encompass a range of conditions characterized by ongoing or recurring headaches. The most common types include migraines, tension headaches, and cluster headaches, each varying in severity and symptomatology.
Migraine headaches are typically associated with pulsating pain, sensitivity to light and sound, and sometimes nausea. In contrast, tension headaches present as a dull, band-like pressure, while cluster headaches are characterised by intense, one-sided pain that occurs in cyclical patterns.
These disorders can severely impact quality of life and work productivity, affecting approximately 40% of the global population, particularly women who are more susceptible to migraines due to hormonal factors. They rank as leading causes of disability, especially for individuals aged 15 to 49.
Current Treatments
Standard treatments for headache disorders include acute medications such as analgesics (NSAIDs, acetaminophen), triptans for migraine relief, and preventive medications like beta-blockers, anticonvulsants, and antidepressants. Non-drug approaches, such as cognitive behavioural therapy, acupuncture, and lifestyle modifications, are also commonly employed.
Psychedelic Effect Matrix
Compound efficacy and evidence levels for Headache Disorders (Cluster & Migraine).
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| LSD Evidence from early studies indicates LSD can stop headache attacks and extend remission, but further trials are needed for standardisation. | Large | Moderate | Inconsistent |
| Psilocybin Initial findings show psilocybin can significantly reduce migraine frequency; however, controlled studies are still ongoing. | Large | Moderate | Inconsistent |
| Ketamine Showing some initial effectiveness for acute cluster headaches, but more extensive research is required. | Medium | Low | Inconsistent |
LSD and Headache Disorders (Cluster & Migraine)
LSD appears to activate 5-HT2A serotonin receptors, playing a critical role in modulating pain signals and affecting the central and peripheral pain systems. This mechanism reduces pain perception and might contribute to anti-inflammatory effects, suggesting a dual approach to managing headaches.
Psilocybin and Headache Disorders (Cluster & Migraine)
Psilocybin's interaction with serotonin receptors also suggests significant potential in pain modulation. Research indicates it may alter pain perception pathways within the brain, potentially leading to significant reductions in headache frequency and intensity via non-hallucinogenic mechanisms.
Ketamine and Headache Disorders (Cluster & Migraine)
Unlike traditional psychedelics, ketamine operates primarily through NMDA receptor antagonism, showing promise in acute headache management. Initial studies indicate its potential in rapidly reducing pain intensity during cluster headaches, although its long-term efficacy requires further investigation.
Clinical Outlook
Ongoing research into psychedelics holds significant potential for revolutionising treatment paradigms for headache disorders. As more clinical trials are underway, particularly focusing on non-hallucinogenic variants, there is optimism that these compounds may transition from experimental options to standardised treatments, providing relief to millions afflicted by these conditions.
Industrial Landscape
Key players in psychedelic research for headache disorders include Ceruvia Lifesciences, which is developing the non-hallucinogenic derivative BOL-148, and Tactogen, focused on novel compounds like TACT908. Additionally, academic institutions and non-profits like Usona Institute are conducting rigorous studies on psychedelics, pushing for integration into mainstream medical practice.
Quick Indicators
Related Topics
Organisations
Search →COMPASS Pathways
COMPASS Pathways is a UK-listed biopharmaceutical company developing COMP360 synthetic psilocybin therapy for treatment-resistant depression, with two successful Phase 3 trials making it the leading candidate for the first regulatory approval of a classic psychedelic medicine.
Ceruvia Lifesciences
Ceruvia Lifesciences is a US-based clinical-stage biopharmaceutical company founded in 2017 by philanthropist Carey Turnbull, focused on developing neurotransformational medicines for neurological and psychiatric disorders. The company was the world's first producer of cGMP-certified LSD and its non-hallucinogenic analogue BOL-148. Ceruvia is advancing SYNP-101 (synthetic psilocybin) through Phase 2 trials for OCD, alcohol use disorder, and migraine/headache disorders, and NYPRG-101 (BOL-148) for cluster headache. Collaborators include Yale University, the Heffter Research Institute, Usona Institute, NYU, and Clusterbusters.
Ketamine Research Institute
The Ketamine Research Institute is a US-based clinical research organization developing precision medicine approaches to ketamine infusion therapy, studying optimized dosing protocols to treat depression and offering clinician training in evidence-based ketamine practice.
University of Basel
The University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti. Research here is primarily focused on the pharmacology of psychoactive substances. Much of the clinical research exploring the effects of LSD is taking place at University Hospital Basel. Researchers here are exploring the potential of LSD to treat Cluster Headache, Major Depressive Disorder and anxiety associated with severe somatic diseases. Professor Liechti is also conducting studies comparing the acute effects of LSD, psilocybin and mescaline, and MDMA for fear extinction.
Leiden University
Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.
Johns Hopkins University
The Centre for Psychedelic and Consciousness Research focuses on how psychedelics affect behavior, cognition, brain function, and biological health markers. They have been at the forefront of demonstrating the safety and efficacy of psychedelics for mental disorders, expanding their focus into psilocybin research across multiple mental health conditions, including smoking cessation, major depressive disorder, and cancer-related anxiety.
Yale University
In 2016, the 'Yale Psychedelic Science Group' was established as a forum where clinicians and scholars from across Yale can learn about and discuss the rapidly re-emerging field of psychedelic science and therapeutics in an academically rigorous manner. Research with psychedelics is also underway at Yale School of Medicine. A recent study at the university found that a single dose of psilocybin can cause structural changes in the brain that counteract symptoms of depression.
Brooke Army Medical Center
Brooke Army Medical Center (BAMC) at Joint Base San Antonio is the US Army's flagship medical institution and the Department of Defense's only Level I Trauma Center, and has been a primary site in multi-center randomized controlled trials investigating ketamine for antidepressant-resistant PTSD in active duty military and veterans. BAMC researchers have also contributed to pilot studies on service members' perspectives on psychedelic-assisted therapies including MDMA and psilocybin for PTSD and traumatic brain injury.
Canisius-Wilhelmina Hospital
Canisius-Wilhelmina Hospital (CWZ) is a major teaching hospital in Nijmegen, Netherlands, whose Department of Neurology has contributed to psychedelic research including an evidence-based review of LSD and psilocybin for chronic pain management, examining serotonin-2A receptor-mediated neuroplastic mechanisms. Situated in the Netherlands—one of Europe’s most active countries for psychedelic research—CWZ participates in neurological research exploring psychedelic compounds as therapeutic agents for pain and psychiatric conditions.
CH TAC LLC
CH TAC LLC (Cluster Headache-Trigeminal Autonomic Cephalalgia, LLC) is a US non-profit research entity that co-sponsored Yale University's Phase 1 psilocybin trials for episodic and chronic cluster headache, in partnership with Heffter Research Institute and Ceruvia Lifesciences.
Institut National de la Santé Et de la Recherche Médicale, France
Institut National de la Santé et de la Recherche Médicale (INSERM) is France's national public health and medical research agency, funding and conducting biomedical research across university-hospital institutes throughout the country. INSERM-affiliated researchers at the Paris Brain Institute (ICM) and Pitié-Salpêtrière Hospital have contributed to preclinical and clinical investigations of ketamine and psilocybin as rapid-acting antidepressants.
Lviv National Medical University
A leading medical research university in Lviv, western Ukraine, founded in 1784 and one of the oldest medical schools in Eastern Europe; Lviv National Medical University researchers have studied ketamine, stellate ganglion block (SGB), and combination approaches for treating traumatic brain injury (TBI)—research carrying particular relevance given Ukraine’s frontline experience with combat-related neurotrauma.
People
Search →Jeanine Kamphuis
Psychiatrist and researcher at the Department for Mood Disorders, University Hospital Groningen (UMCG)
She studies ketamine, esketamine, and classic psychedelics for treatment-resistant psychiatric disorders, including depression, and is a coauthor on multiple psychedelic/ketamine reviews and clinical studies.
Joost Breeksema
Postdoctoral researcher and Executive Director of the OPEN Foundation
He is a prominent psychedelic researcher and advocate whose work helps shape evidence-based psychedelic policy, ethics, and patient-centered understanding of psychedelic and ketamine/esketamine treatments.
Mathieu Seynaeve
Senior Medical Director and Head of Psychotherapy at Beckley Psytech
He is a clinical development leader behind multiple human studies of 5-MeO-DMT and psilocybin, including trials in alcohol use disorder, treatment-resistant depression, and headache disorders.
Kayla Teopiz
Researcher in psychiatry and ketamine/psychedelic medicine research; likely affiliated with the University of Toronto/Trillium Health Partners research network
Teopiz coauthors multiple systematic reviews and clinical studies on ketamine, esketamine, and psilocybin in depression and suicidality, helping synthesize the evidence base for psychedelic and glutamatergic treatments in psychiatry.
John Kelly
Associate Professor / Consultant General Psychiatrist at Trinity College Dublin
John R. Kelly is a leading academic psychiatrist in Ireland whose work has helped shape modern psychedelic psychiatry, including psilocybin research across depression, service-user attitudes, and transdiagnostic treatment frameworks.
Valerie Bonnelle
Scientific Assistant to the Director at the Beckley Foundation
She is a researcher coordinating psychedelic studies on microdosing, pain, autonomic physiology, and peak experiences, contributing to the clinical and mechanistic understanding of psychedelic effects.
Yvan Beaussant
Instructor in Medicine at Harvard Medical School and palliative care physician at Dana-Farber Cancer Institute
He is a leading clinical researcher in psychedelic-assisted therapy for serious illness, especially cancer-related depression, demoralization, and existential distress.
Tomislav Majic
Senior physician and Head of the Psychotropic Substances Research Group at Charité – Universitätsmedizin Berlin
He is a psychiatrist and psychedelics researcher at Charité who has helped lead clinical and observational work on serotonergic psychedelics and related substances, including their therapeutic potential and risks.
Bing Cao
PhD researcher at the Key Laboratory of Cognition and Personality, Faculty of Psychology, Southwest University
He is a recurring coauthor on multiple ketamine and psychedelic-adjacent systematic reviews and mechanistic studies, making him a visible contributor to contemporary rapid-acting antidepressant research.
Scott Tyler Aaronson
Chief Science Officer, Institute for Advanced Diagnostics and Therapeutics at Sheppard Pratt; Adjunct Professor of Psychiatry, University of Maryland School of Medicine
He is a leading psychiatrist in treatment-resistant depression and a key investigator on psilocybin studies, including work on preparation, dosing, outcomes, and mechanisms of psychedelic-assisted therapy.
Anna Ermakova
Research Scientist at Beckley Psytech and psychedelic research contributor
She is an author on multiple influential 5-MeO-DMT clinical and review papers, helping build the evidence base for psychedelic therapies in depression and alcohol use disorder.
Catherine Bird
Senior Clinical Trials Manager at King’s College London
She is a key clinical trials researcher in major psychedelic studies, including psilocybin trials for treatment-resistant depression and related neuropsychiatric conditions.
Connected Evidence
The latest clinical data and verified academic findings associated with Headache Disorders (Cluster & Migraine).